On the stock market since 2025, it operates in the world of health and science. It has 1,212 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $244.5M a year. A small number, but proof the product has real buyers.
There is $25.2B in the vault; even if every debt were paid off, $25.1B would remain.
The average analyst price target is $28.50 — 31% above today’s price.
A loss of $358K against $244.5M in annual sales.
On our five-subject report card, PARK sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PARK is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (54/100) says the stock isn’t cheap.